에 대한 최신 뉴스 Medtronic (NYSE:MDT) 주식

Medtronic

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

NVDA

SERV

SOUN

CNN 머니 공포·탐욕 지수는 전체 시장 심리의 개선을 나타냈으며 지난 금요일(14일) &#34;공포&#34; 영역에 있었다.

다우 지수 150p 이상 하락했으나 주간 상승 기록: 투자 심리 개선, 탐욕 지수는 &#39;공포&#39; 영역

BIDU

SOHU

화요일(18일) 아침 미국 주식 선물이 상승하는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식들은 다음과 같다. 메드트로닉, 바이두, 소후닷컴, 플루오르 및 옥시덴탈 페트롤리엄

화요일 주목해야 할 주식: 메드트로닉, 바이두, 소후닷컴, 플루오르 및 옥시덴탈 페트롤리엄

TSLA

CNN 머니 공포·탐욕 지수는 전체 시장 심리가 다소 개선되었음을 보여 주면서 화요일에는 &#34;중립&#34; 영역에 머물렀다.화요일(19일) 미국 증시는 혼조세를 보였으며, 나스닥 지수는 약 1% 상승했다. 이는 투자자들이 우크라이나와 러시아 간의 상승하는 지정학적 우려를 과소평가했기 때문이다.

엔비디아 실적 발표 앞두고 나스닥 1% 상승: 투자심리 개선, 공포·탐욕 지수는 &#39;중립&#39; 영역

Medtronic PLC

Measurable Data Token - United States Dollar

MEDIA TECHS INC by Media Technologies Inc.

Media Technologies Inc

MEDIA TEK INC by Media Tek Inc.

MANDATUM OYJ U/ADR by MANDATUM OYJ

MediaTek Inc

MEDITERRANEAN TOWERS LTD by Mediterranean Towers LTD

Mediterranean Towers Ltd

On Monday, the FDA approved Medtronic plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43911731/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-p" rel="noreferrer noopener">with Parkinson&#8217;s disease</a>.
Deep brain stimulation uses a surgically implanted neurostimulator via a minimally invasive procedure to transmit electrical signals to specific parts of the brain affected by debilitating neurological disorders.
Medtronic has enhanced its Percept DBS neurostimulators with exclusive BrainSense Adaptive technology for Parkinson&#8217;s.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43782957/medtronic-q3-earnings-cardiovascular-and-neuroscience-drive-growth-surgical-revenue-dips-reaffirms-annual-forecast" rel="noreferrer noopener">Medtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast</a>
This feature personalizes therapy based on a patient&#8217;s brain activity in real-time – both in clinical settings and daily life.
It provides enhanced therapy personalization for symptom control that automatically adjusts, minimizing the need for patients to manually adjust stimulation.
BrainSense Adaptive DBS is available to Medtronic DBS patients with Parkinson&#8217;s who have been implanted with a Percept neurostimulator and future Medtronic DBS patients.
The Medtronic Adaptive DBS Algorithm for Personalized Therapy in Parkinson&#8217;s Disease (ADAPT-PD) trial highlights the potential of aDBS in clinical practice.
The FDA approval also includes the Medtronic BrainSense Electrode Identifier (EI), which helps reduce patient time spent in clinic to program their DBS settings. Using EI, clinicians can conduct an accurate and precise initial programming, 85% faster than traditional electrode selection.
BrainSense aDBS and EI are also&nbsp;available&nbsp;in&nbsp;Europe. Patient programs in&nbsp;the United States&nbsp;will begin at select healthcare systems over the coming weeks, with availability nationwide in the coming months.
Price Action: MDT stock is up 0.85% at $90.70 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/02/43910982/apple-commits-500-billion-in-us-investment-for-ai-push-boost-us-manufacturing-tech" target="_blank" rel="noreferrer noopener">Apple Commits $500 Billion In US Investment For AI Push, Boost US Manufacturing Tech</a></li>
</ul>
Photo via Shutterstock

Large Cap

Health Care

General

FDA Approves Medtronic's Adaptive Deep Brain Stimulation System For Parkinson's Patients

New closed-loop system self-adjusts DBS therapy to individual brain activity&nbsp;in real time; the largest commercial launch of brain-computer interface technology ever&nbsp;
GALWAY, Ireland, Feb. 24, 2025 /PRNewswire/ --&nbsp;For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense&#x2122; Adaptive deep brain stimulation (aDBS) and BrainSense&#x2122; Electrode Identifier (EI).
There is no cure for debilitating neurological conditions like Parkinson's, however, deep brain stimulation (DBS) has been transforming the lives of people with Parkinson's and other neurological disorders for more than 30 years. DBS is similar to a cardiac pacemaker, but for the brain. It uses a surgically implanted neurostimulator via a minimally invasive procedure to transmit electrical signals to specific parts of the brain affected by debilitating neurological disorders.
Now Medtronic has enhanced its Percept&#x2122; DBS neurostimulators with exclusive BrainSense&#x2122; Adaptive technology†, introducing aDBS for people living with Parkinson's. This feature personalizes therapy based on a patient's brain activity in real time – both in clinical settings and in daily life2. It provides enhanced therapy personalization for symptom control that automatically adjusts, minimizing the need for patients to manually adjust stimulation.

Biotech

Medtronic Earns U.S. FDA Approval For The World's First Adaptive Deep Brain Stimulation System For People With Parkinson's

RBC Capital analyst Shagun Singh reiterates Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Outperform and maintains $105 price target.

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Outperform on Medtronic, Maintains $105 Price Target

UBS analyst Danielle Antalffy maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Neutral and raises the price target from $85 to $95.

UBS Maintains Neutral on Medtronic, Raises Price Target to $95

Baird analyst David Rescott maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Neutral and raises the price target from $90 to $91.

Baird Maintains Neutral on Medtronic, Raises Price Target to $91

Needham analyst Mike Matson reiterates Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from Hold to Hold.

Needham Reiterates Hold on Medtronicto Hold

Major U.S. indices are little-changed in Tuesday's midday trading as investors monitor recent geopolitical developments and anticipate the release of the latest FOMC<a href="https://www.benzinga.com/25/02/43784079/us-stocks-mixed-ny-state-business-activity-rises-in-february"> minutes on Wednesday.</a>
U.S. and Russian officials met in Saudi Arabia Tuesday <a href="https://www.benzinga.com/news/global/25/02/43787369/us-russian-officials-begin-ukraine-peace-talks-defense-sector-stocks-rise">to begin</a> peace negotiations, marking their first high-level talks on the war in Ukraine since Russia&#8217;s invasion in 2022. The initial talks were intended as "trust-building" and could lay the groundwork for a future meeting between President Donald Trump and Russian President Vladimir Putin. Ukrainian and other European officials were notably absent from Tuesday's discussions. 
WTI crude oil futures held steady as diplomatic talks between the U.S. and Russia raised hopes for reduced geopolitical risks. 
Read Next: <a href="https://www.benzinga.com/25/02/43703014/robert-f-kennedy-confirmed-as-trump-secretary-of-health">Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump&#8217;s Secretary Of Health: Health Care Stocks To Watch</a>
The yield on the 10-year US Treasury note rose 0.04%, back above the 4.5% threshold as investors digested recent comments from Fed officials, including Christopher Waller, Michelle Bowman and Patrick Harker, which reinforced expectations that interest rates will remain on hold in the near term.  
All eyes will be on Wednesday's release of the latest FOMC's minutes set for 2 p.m. ET. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) fell 0.57% to $88.64.&nbsp;
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was down 1.16% to $94,672 as crypto markets fell broadly Tuesday.&nbsp;&nbsp;
<h2 class="wp-block-heading">Tuesday's Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,000.73</td>
<td>-0.12%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,115.46</td>
<td>0.01%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,454.56</td>
<td>-0.19%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,288.09</td>
<td>0.36%</td>
</tr>
</tbody>
</table>
</figure>
According to Benzinga Pro data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched up 0.1% to $610.31.&nbsp;</li>
<li>The SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was down 0.17% at $445.03.&nbsp;</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.04% to $538.36.&nbsp;</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.44% to $226.97.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) dipped 0.53% to $225.81.&nbsp;</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) rose 0.95% to $90.93.&nbsp;</li>
</ul>
<h2 class="wp-block-heading">Tuesday's Stock Movers:&nbsp;</h2>
Shares of Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) surged following reports suggesting Broadcom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) and Taiwan Semiconductor Manufacturing Co. Ltd.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) are <a href="https://www.benzinga.com/markets/equities/25/02/43775200/intel-jumps-over-5-in-tuesday-pre-market-as-deal-talks-with-broadcom-and-tsmc-surface">considering bids</a> for portions of the company.
Stocks reacting to company earnings reports included:&nbsp;
<ul>
<li>Baidu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>)&nbsp;</li>
<li>Constellation Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)&nbsp;</li>
<li>Franklin Electric Co., Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FELE#NASDAQ">FELE</a>)&nbsp;</li>
<li>Watsco, Inc.&nbsp; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>)&nbsp;</li>
<li>Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>)&nbsp;</li>
<li>Donnelley Financial Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFIN#NYSE">DFIN</a>)&nbsp;</li>
<li>Fluor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>)&nbsp;</li>
<li>Medtronic Plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)&nbsp;</li>
<li>GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>)&nbsp;</li>
<li>Entergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>)&nbsp;</li>
<li>iQIYI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>)&nbsp;</li>
</ul>
Companies reporting after Tuesday's closing bell include:&nbsp;
<ul>
<li>Occidental Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>)&nbsp;</li>
<li>Matador Resources Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>)&nbsp;</li>
<li>Devon Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>)&nbsp;</li>
<li>Bumble, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>)&nbsp;</li>
<li>Sonoco Products Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SON#NYSE">SON</a>)&nbsp;</li>
<li>Toll Brothers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>)&nbsp;</li>
<li>Star Bulk Carriers Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBLK#NASDAQ">SBLK</a>)&nbsp;</li>
<li>Shift4 Payments, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>)&nbsp;</li>
<li>Matador Resources Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>)</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/02/43732115/explosion-rocks-chernobyl-nuclear-site-as-zelenskyy-signals-readiness-for-peace-talks">Explosion Rocks Chernobyl Nuclear Site As Zelenskyy Signals Readiness For Peace Talks</a>&nbsp;</li>
</ul>
Image: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Market Summary

Broad U.S. Equity ETFs

Commodities

Global

Federal Reserve

Movers

Tech

ETFs

$BTC

AVGO

AXSM

BMBL

DFIN

SPDR Dow Jones Industrial Average ETF Trust

FELE

FOUR

INTC

MTDR

SBLK

iShares Trust Barclays 20+ Year Treasury Bond Fund

Select Sector SPDR-Consumer Discretionary

US, Russia Begin Ukrainian Peace Talks, Intel Shares Surge: What's Driving Markets Tuesday?

Tuesday,&nbsp;Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported third-quarter 2025 sales of $8.29 billion, missing the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $8.32 billion</a>.
The medical device maker reported adjusted EPS of $1.39, beating the consensus of $1.36. Revenue increased 2.5% year over year, as reported,&nbsp;and 4.1% organically.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/01/42859544/anteris-technologies-positioned-to-capture-4-5-of-us-transcatheter-valve-replacement-market-by-2030-analyst" rel="noreferrer noopener">Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst</a>
&#8220;We delivered strong earnings this quarter, with significant improvements in both our gross margin and operating margin on the back of our ninth quarter in a row of mid-single digit organic revenue growth,&#8221; said&nbsp;Geoff Martha, Medtronic chairman and chief executive officer.
&#8220;We are starting to see the results from our long-term investments in groundbreaking innovation, such as pulsed-field ablation, to drive growth in some of the most attractive markets in MedTech.&#8221;
Cardiovascular segment revenue reached&nbsp;$3.04 billion, up 3.7% year over year as reported, and&nbsp;increased 5% organically, with mid-single digit increases in Cardiac Rhythm &amp; Heart Failure and Structural Heart &amp; Aortic and a low-single-digit increase in Coronary &amp; Peripheral Vascular, all on <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43776497/medtronic-reports-third-quarter-fiscal-2025-financial-results" rel="noreferrer noopener">an organic basis</a>.
Neuroscience revenues of&nbsp;$2.46 billion&nbsp;increased 4.4% as reported and 5.2% organically, with a low-double-digit increase in Neuromodulation, mid-single-digit increase in Cranial &amp; Spinal Technologies, and low-single-digit increase in Specialty Therapies, all on an organic basis.
Medical Surgical revenue of $2.07 billion decreased by 1.9% as reported and by 0.4% organically, with flat organic results in Surgical &amp; Endoscopy and a low-single-digit organic decline in Acute Care &amp; Monitoring.
Diabetes revenue of&nbsp;$694 million&nbsp;increased by 8.4%, as reported, and by 10.4% organic.
Guidance:&nbsp;Medtronic reaffirms its fiscal year 2025 organic revenue <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/42069216/medtronic-q2-earnings-diabetes-and-neuroscience-revenue-boost-growth-raises-annual-outlook" rel="noreferrer noopener">growth guidance of 4.75%-5%</a>.
If recent foreign currency exchange rates hold, FY25 revenue growth would be around 3.4%-3.8%. If recent foreign currency exchange rates hold, 2025 revenue growth on an adjusted basis would be 3.4%-3.9%.
Medtronic expects 2025 adjusted EPS of $5.44-$5.50 versus consensus of $5.45.
Price Action: MDT stock is down 5.94% at $87.30 during the premarket session at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43778628/fda-approves-gsks-5-in-1-meningococcal-vaccine-for-adolescents-ahead-of-cdc-advisory-committee-vote-meeting-next-week" target="_blank" rel="noreferrer noopener">FDA Approves GSK&#8217;s 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory Committee Vote Meeting Next Week</a></li>
</ul>
Photo via Shutterstock

Guidance

Medtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast

CORRECTION: Medtronic Affirms FY25 Adj EPS Outlook of $5.44-$5.50 vs $5.45 Estimate; Narrows FY25 Sales Guidance from $33.46B-$33.63B To $33.46B-$33.59B vs $33.54B Estimate

WIIM

Medtronic shares are trading lower after the company reported mixed Q3 financial results and issued FY25 adjusted EPS guidance below estimates.

Medtronic Reaffirms Its FY25 Organic Revenue Growth Guidance Of 4.75%-5%

Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported quarterly earnings of $1.39 per share which beat the analyst consensus estimate of $1.36 by 2.21 percent. This is a 6.92 percent increase over earnings of $1.30 per share from the same period last year. The company reported quarterly sales of $8.29 billion which missed the analyst consensus estimate of $8.32 billion by 0.39 percent. This is a 2.51 percent increase over sales of $8.09 billion the same period last year.

Medtronic Q3 2025 Adj EPS $1.39 Beats $1.36 Estimate, Sales $8.29B Miss $8.32B Estimate

U.S. stock futures rose on Tuesday after a long weekend following a mixed close on Friday. Monday was a federal holiday owing to the Presidents Day celebrations. The futures of all four benchmark indices advanced.
Investors will be on the lookout for global macroeconomic factors as the U.S. and Russian officials met in Riyadh on Tuesday for their highest-level talks yet on the Ukraine war.
Discussions focused on ending the three-year conflict and improving relations, potentially paving the way for a summit between Presidents Donald Trump and Vladimir Putin.
Walmart Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) earnings will be a key focus this week, along with reports from U.S.-listed Chinese e-commerce giants Alibaba Group Holding ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) and Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>). Online used-car retailer Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>), and EV maker Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) will also report this week.
The 10-year Treasury yield stood at 4.50%, while the two-year yield was at 4.27%. According to the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, there is a 97.5% chance that the Federal Reserve will keep interest rates unchanged for the March meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.37%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.29%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.10%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.15%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Tuesday. SPY rose 0.30% to $611.52, and QQQ advanced 0.42% to $540.42, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Tech and Communication Services bucked the negative trend, closing higher on Friday, while Healthcare, Consumer Staples, and Utilities led losses as most S&amp;P 500 sectors declined. 
Despite Friday&#8217;s mixed results, for the last week, the S&amp;P 500 gained 1.5%, the Dow 0.6%, and the Nasdaq 2.6% led by weaker-than-expected retail sales which were down 0.9% in January.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.41%</td>
<td>20,026.77 </td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.0072%</td>
<td>6,114.63</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.37%</td>
<td>44,546.08</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.097%</td>
<td>2,279.98</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
Ryan Detrick, the chief market strategist at Carson Research pointed out that seven out of the total broad 11 sectors have outperformed the S&amp;P 500 index on a year-to-date basis.
&#8220;We&#8217;ve been pounding the table for broadening out and we think this will continue,&#8221; he added.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">After a big week for tech last week, all 11 sectors are up on the year and seven groups are outperforming the S&amp;P 500. We&#39;ve been pounding the table for broadening out and we think this will continue. <a href="https://t.co/F2sPwCw8wj">pic.twitter.com/F2sPwCw8wj</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1891675975995244713?ref_src=twsrc%5Etfw">February 18, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The S&amp;P 500 has surged 60% in the past two years, a significant increase. However, according to Bravos Research historically, similar rapid gains have often been followed by substantial market downturns.
The downturns have occurred three out of the last four times after such a surge was witnessed. Bravos highlights that one instance did lead to a rapid and dramatic market rise, calling it a &#8220;melt-up.&#8221;
The question, now is whether the current situation will follow the more common pattern of decline or the rarer &#8220;melt-up&#8221; scenario.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">S&amp;P 500 has seen a 60% gain in just 2 years The last 3 out of 4 times saw big market declines after But 1 time it did end up in a true melt-up Which one is it going to be this time around? <a href="https://t.co/QywZJANK2U">pic.twitter.com/QywZJANK2U</a>
&mdash; Bravos Research (@bravosresearch) <a href="https://twitter.com/bravosresearch/status/1891174402554802495?ref_src=twsrc%5Etfw">February 16, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Talking about the economic impact Ed Yardeni in his Market Call blog said, &#8220;So far, Trump&#8217;s tariff turmoil seems to be weighing more on the U.S., Canada, Mexico, and many other emerging markets than on China and most European countries.&#8221;
That could change once reciprocal tariffs are imposed by the U.S. in early April, unless Trump changes his mind, again, added Yardeni.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on this week:
<ul>
<li>On Tuesday, February&#8217;s Empire State manufacturing survey data will be released at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>February&#8217;s home builder confidence index will be announced at 10:00 a.m., ET.</li>
</ul>
<ul>
<li>San Francisco Fed President Mary C Daly will speak at 10:20 a.m., while Fed Vice Chairman for Supervision Michael Barr will speak at 1:00 p.m., ET.</li>
</ul>
<ul>
<li>On Wednesday, January&#8217;s housing starts and building permits data will be out by 8:30 a.m., ET.</li>
</ul>
<ul>
<li>January&#8217;s minutes of the Federal Reserve Open Market Committee meeting will be released at 2:00 p.m., ET.</li>
</ul>
<ul>
<li>Fed Vice Chairman Philip Jefferson will speak at 5:00 p.m., ET.</li>
</ul>
<ul>
<li>On Thursday, initial jobless claims till Feb. 15 will be announced and the Philadelphia Fed manufacturing survey for Feb will be out by 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Chicago Fed President Austan Goolsbee will be speaking at 09:35 a.m., ET.</li>
</ul>
<ul>
<li>January&#8217;s leading economic indicators will be released at 10:00 a.m., ET.</li>
</ul>
<ul>
<li>Vice Chairman for Supervision Michael Barr will speak again at 2:30 p.m., ET.</li>
</ul>
<ul>
<li>Fed Governor Adriana Kugler will be speaking at 5:00 p.m., ET.</li>
</ul>
<ul>
<li>On Friday, February&#8217;s S&amp;P flash U.S. services PMI and manufacturing PMI will be out by 9:45 a.m., ET.</li>
</ul>
<ul>
<li>The final consumer sentiment data for February and existing home sales data for January will be out by 10:00 a.m., ET.</li>
</ul>
<ul>
<li>Fed Vice Chairman Philip Jefferson will speak again and San Francisco Fed President Mary C Daly will also speak at 11:30 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Medtronic PLC. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) was up 0.75% in the premarket on Tuesday ahead of its earnings, which will be released before the opening bell. Analysts expect it to report quarterly earnings of $1.36 per share on revenue of $8.32 billion.</li>
</ul>
<ul>
<li>Fluor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) advanced 1.34% as Wall Street expects it to report quarterly earnings of 77 cents per share on revenue of $4.42 billion before the opening bell.</li>
</ul>
<ul>
<li>Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) dropped 2.28% ahead of its earnings, which will be released before the opening bell. Analysts expect it to report quarterly earnings of $1.78 per share on revenue of $4.56 billion.</li>
</ul>
<ul>
<li>Occidental Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) jumped 1.64% as Wall Street expects it to report quarterly earnings of 70 cents per share on revenue of $7.05 billion after the closing bell.</li>
</ul>
<ul>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) climbed 17.78% after securing two funding agreements; a $25 million committed equity facility allowing them to sell shares to an investor over two years, and a $1 million at-the-market facility for Nasdaq share sales.</li>
</ul>
<ul>
<li>Pagaya Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) zoomed 23.68% after posting record total revenue and other income of $279 million in the fourth quarter along with a record network volume of $2.6 billion.</li>
</ul>
<ul>
<li>MGO Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) plunged 26.42% as shareholders approved the proposed business combination with Heidmar at a special meeting on Friday.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 1.56% to hover around $71.81 per barrel.
The gold spot index was up by 0.48% to $2,912.19 per ounce. The Dollar Index was up 0.34% at 106.932 level.
Asian markets were mixed on Tuesday. Australia's ASX 200, China's CSI 300, and India's S&amp;P BSE Sensex index fell. Whereas, South Korea's Kospi, Hong Kong's Hang Seng, and Japan's Nikkei 225 index advanced. European markets were mixed in trade as well.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43774256/gop-megadonor-ken-griffins-citadel-earns-77-return-from-palantir-despite-slashing-13-in-q4-adds-4-mag-7-while-cut">GOP Megadonor Ken Griffin&#8217;s Citadel Scores 77% Return On Palantir Despite Trimming Stake, Doubles Down On These 4 &#8216;Mag 7&#8217; Stocks</a></li>
</ul>
Photo courtesy: Shutterstock

Government

Treasuries

Economics

APTO

BABA

CVNA

MGOL

RIVN

US Stocks Likely To Open Higher Amid Ukraine Peace Talk Hopes As Russian, American Officials Meet

<h3>Companies Reporting Before The Bell</h3>
• Sohu.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHU#NASDAQ">SOHU</a>) is estimated to report earnings for its fourth quarter. 
• Expeditors Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPD#NYSE">EXPD</a>) is projected to report quarterly earnings at $1.44 per share on revenue of $2.81 billion. 
• Franklin Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FELE#NASDAQ">FELE</a>) is expected to report quarterly earnings at $0.66 per share on revenue of $465.87 million. 
• Valmont Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) is estimated to report quarterly earnings at $3.62 per share on revenue of $1.01 billion. 
• GeneDx Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $82.24 million. 
• Watsco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>) is projected to report quarterly earnings at $2.19 per share on revenue of $1.67 billion. 
• Hillman Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $350.45 million. 
• Vulcan Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) is estimated to report quarterly earnings at $1.75 per share on revenue of $1.81 billion. 
• NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $173.40 million. 
• Donnelley Financial Solns (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFIN#NYSE">DFIN</a>) is estimated to report quarterly earnings at $0.49 per share on revenue of $169.20 million. 
• Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) is projected to report quarterly loss at $0.99 per share on revenue of $117.83 million. 
• Genuine Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) is estimated to report quarterly earnings at $1.55 per share on revenue of $5.71 billion. 
• Visteon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VC#NASDAQ">VC</a>) is likely to report quarterly earnings at $1.97 per share on revenue of $954.17 million. 
• Chemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $1.37 billion. 
• Sapiens Intl Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPNS#NASDAQ">SPNS</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $135.89 million. 
• Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) is likely to report quarterly earnings at $0.77 per share on revenue of $4.42 billion. 
• Allegion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLE#NYSE">ALLE</a>) is expected to report quarterly earnings at $1.75 per share on revenue of $938.91 million. 
• iQIYI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $909.96 million. 
• Entergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) is projected to report quarterly earnings at $0.64 per share on revenue of $3.17 billion. 
• Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) is expected to report quarterly earnings at $1.78 per share on revenue of $4.56 billion. 
• Great Lakes Dredge &amp; Dock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLDD#NASDAQ">GLDD</a>) is likely to report quarterly earnings at $0.23 per share on revenue of $211.20 million. 
• Blackbaud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLKB#NASDAQ">BLKB</a>) is likely to report quarterly earnings at $1.07 per share on revenue of $303.41 million. 
• Waystar Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAY#NASDAQ">WAY</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $232.29 million. 
• Tri Pointe Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPH#NYSE">TPH</a>) is expected to report quarterly earnings at $1.29 per share on revenue of $1.22 billion. 
• Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) is projected to report quarterly earnings at $1.36 per share on revenue of $8.33 billion. 
<h3>Companies Reporting After The Bell</h3>
• James Hardie Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) is expected to report quarterly earnings at $0.36 per share on revenue of $960.80 million. 
• RB Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBA#NYSE">RBA</a>) is projected to report quarterly earnings at $0.79 per share on revenue of $1.06 billion. 
• Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) is expected to report earnings for its first quarter. 
• Safe Bulkers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SB#NYSE">SB</a>) is projected to report quarterly earnings at $0.16 per share on revenue of $71.90 million. 
• ReNew Energy Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNW#NASDAQ">RNW</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $264.79 million. 
• Select Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTTR#NYSE">WTTR</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $338.92 million. 
• Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) is expected to report quarterly earnings at $0.28 per share on revenue of $85.39 million. 
• TPG RE Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRTX#NYSE">TRTX</a>) is projected to report quarterly earnings at $0.26 per share on revenue of $27.98 million. 
• SiriusPoint (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPNT#NYSE">SPNT</a>) is likely to report earnings for its fourth quarter. 
• Star Bulk Carriers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBLK#NASDAQ">SBLK</a>) is expected to report quarterly earnings at $0.44 per share on revenue of $238.48 million. 
• TrueCar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUE#NASDAQ">TRUE</a>) is expected to report quarterly loss at $0.02 per share on revenue of $47.30 million. 
• BlueLinx Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXC#NYSE">BXC</a>) is likely to report quarterly earnings at $0.52 per share on revenue of $700.66 million. 
• Compass (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>) is projected to report quarterly loss at $0.03 per share on revenue of $1.29 billion. 
• Medifast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) is projected to report quarterly loss at $0.16 per share on revenue of $114.25 million. 
• Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) is projected to report quarterly loss at $0.05 per share on revenue of $3.14 billion. 
• Brookdale Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKD#NYSE">BKD</a>) is expected to report quarterly loss at $0.24 per share on revenue of $781.68 million. 
• Perdoceo Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRDO#NASDAQ">PRDO</a>) is estimated to report quarterly earnings at $0.48 per share on revenue of $160.12 million. 
• Iamgold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) is likely to report earnings for its fourth quarter. 
• La-Z-Boy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LZB#NYSE">LZB</a>) is estimated to report quarterly earnings at $0.67 per share on revenue of $516.47 million. 
• CVR Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAN#NYSE">UAN</a>) is likely to report earnings for its fourth quarter. 
• CVR Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVI#NYSE">CVI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $1.93 billion. 
• Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) is likely to report quarterly earnings at $1.17 per share on revenue of $286.07 million. 
• Sonoco Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SON#NYSE">SON</a>) is likely to report quarterly earnings at $1.22 per share on revenue of $1.65 billion. 
• CoStar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $701.59 million. 
• Bel Fuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELFB#NASDAQ">BELFB</a>) is expected to report quarterly earnings at $0.78 per share on revenue of $123.21 million. 
• Bel Fuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELFA#NASDAQ">BELFA</a>) is estimated to report quarterly earnings at $1.01 per share on revenue of $128.50 million. 
• Arteris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIP#NASDAQ">AIP</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $15.18 million. 
• Unisys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UIS#NYSE">UIS</a>) is estimated to report quarterly earnings at $0.30 per share on revenue of $550.93 million. 
• Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) is expected to report quarterly earnings at $2.05 per share on revenue of $1.91 billion. 
• XP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>) is estimated to report quarterly earnings at $0.40 per share on revenue of $828.34 million. 
• Element Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $600.32 million. 
• Quad/Graphics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QUAD#NYSE">QUAD</a>) is projected to report quarterly earnings at $0.38 per share on revenue of $726.70 million. 
• Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) is estimated to report quarterly earnings at $0.31 per share on revenue of $260.00 million. 
• Center (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSR#NYSE">CSR</a>) is estimated to report quarterly earnings at $1.19 per share on revenue of $65.70 million. 
• Flowserve (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) is projected to report quarterly earnings at $0.77 per share on revenue of $1.21 billion. 
• Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) is expected to report quarterly earnings at $0.20 per share on revenue of $12.00 million. 
• Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) is likely to report quarterly earnings at $0.84 per share on revenue of $2.69 billion. 
• SSR Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSRM#NASDAQ">SSRM</a>) is expected to report quarterly earnings at $0.20 per share on revenue of $244.25 million. 
• BrightSpire Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRSP#NYSE">BRSP</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $48.20 million. 
• Corporacion Inmobiliaria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTMX#NYSE">VTMX</a>) is likely to report earnings for its fourth quarter. 
• Hackett Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCKT#NASDAQ">HCKT</a>) is expected to report quarterly earnings at $0.41 per share on revenue of $75.64 million. 
• Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) is projected to report quarterly earnings at $0.57 per share on revenue of $1.90 billion. 
• Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) is expected to report quarterly earnings at $0.90 per share on revenue of $311.52 million. 
• JBG SMITH Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBGS#NYSE">JBGS</a>) is projected to report earnings for its fourth quarter. 
• Seven Hills Realty Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEVN#NASDAQ">SEVN</a>) is estimated to report quarterly earnings at $0.34 per share on revenue of $8.31 million. 
• Industrial Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILPT#NASDAQ">ILPT</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $110.30 million. 
• Matador Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>) is estimated to report quarterly earnings at $1.84 per share on revenue of $999.09 million. 
• Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) is projected to report quarterly earnings at $0.74 per share on revenue of $7.04 billion. 
• Community Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHCT#NYSE">CHCT</a>) is expected to report quarterly earnings at $0.54 per share on revenue of $29.90 million. 
• Adeia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADEA#NASDAQ">ADEA</a>) is estimated to report quarterly earnings at $0.42 per share on revenue of $113.93 million. 
• Rush Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUSHB#NASDAQ">RUSHB</a>) is expected to report earnings for its fourth quarter. 
• Rush Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUSHA#NASDAQ">RUSHA</a>) is projected to report quarterly earnings at $0.83 per share on revenue of $1.86 billion. 
• Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) is expected to report quarterly earnings at $1.20 per share on revenue of $997.44 million. 
• Ingevity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) is expected to report quarterly earnings at $0.30 per share on revenue of $315.20 million. 
• Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) is estimated to report quarterly earnings at $1.25 per share on revenue of $2.39 billion. 
• MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) is likely to report quarterly earnings at $0.38 per share on revenue of $722.85 million. 
• Gladstone Commercial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOD#NASDAQ">GOOD</a>) is estimated to report quarterly earnings at $0.36 per share on revenue of $38.20 million. 
• EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) is expected to report quarterly earnings at $0.50 per share on revenue of $1.82 billion. 
• Comstock Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRK#NYSE">CRK</a>) is likely to report quarterly earnings at $0.03 per share on revenue of $378.74 million. 
• Genworth Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNW#NYSE">GNW</a>) is likely to report earnings for its fourth quarter. 
• Innospec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOSP#NASDAQ">IOSP</a>) is estimated to report quarterly earnings at $1.37 per share on revenue of $447.40 million. 
• Magnolia Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGY#NYSE">MGY</a>) is projected to report quarterly earnings at $0.48 per share on revenue of $330.88 million. 
• Sasol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) is expected to report earnings for its fourth quarter. 
• Sandstorm Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAND#NYSE">SAND</a>) is expected to report earnings for its fourth quarter. 
• Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) is expected to report quarterly earnings at $1.31 per share on revenue of $4.30 billion. 
• Cadence Design Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) is estimated to report quarterly earnings at $1.83 per share on revenue of $1.35 billion. 
• Ternium (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TX#NYSE">TX</a>) is projected to report quarterly earnings at $1.28 per share on revenue of $4.49 billion. 
• Andersons (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANDE#NASDAQ">ANDE</a>) is likely to report quarterly earnings at $0.94 per share on revenue of $2.73 billion. 
• Liberty Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBTYA#NASDAQ">LBTYA</a>) is likely to report quarterly loss at $0.96 per share on revenue of $1.95 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADEA

ALLE

ANDE

ANET

BELFA

BELFB

BLKB

BRSP

CDNS

CHCT

COMP

CSGP

EXPD

GLDD

GOOD

HALO

HCKT

HLMN

ILPT

IOSP

JBGS

LBTYA

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

MOBX

NGVT

PRDO

QUAD

RUSHA

RUSHB

SAND

SEVN

SMLR

SPNS

SPNT

SSRM

TCMD

TRTX

TRUE

VTMX

WTTR

Earnings Scheduled For February 18, 2025

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, with the index in the &#8220;Fear&#8221; zone on Friday.
U.S. stocks settled mixed on Friday, with the Dow Jones index falling more than 150 points during the session.
However, stocks recorded gains last week, with the S&amp;P 500 gaining around 1.5% and the Dow rising 0.6%. The Nasdaq gained 2.6% during the week.
Traders digested weaker-than-expected retail sales and the potential for peace talks between Russia and Ukraine. Retail sales in the U.S. fell 0.9% month-over-month in January, significantly worse than the anticipated 0.1% drop.
SoundHound AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) shares dipped 28% on Friday after Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) disclosed in a 13F filing that it dissolved its stake in the company. Shares of Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) tumbled 40% after an amended 13G filing shows Nvidia holds no stake in the company.
Most sectors on the S&amp;P 500 closed on a negative note, with healthcare, consumer staples, and utilities stocks recording losses on Friday. However, information technology and communication services stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 165 points to 44,546.08 on Friday. The S&amp;P 500 fell 0.01% to 6,114.63, while the Nasdaq Composite jumped 0.41% to 20,026.77 during Friday's session.
Investors are awaiting earnings results from Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), Occidental Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>), and Fluor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 44.5, the index was in the &#8220;Fear&#8221; zone on Friday, versus a prior reading of 43.3.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43730195/top-3-defensive-stocks-that-may-collapse-in-q1">Top 3 Defensive Stocks That May Collapse In Q1</a></li>
</ul>
Photo courtesy: Shutterstock

Dow Dips Over 150 Points, But Records Weekly Gain: Investor Sentiment Improves, Greed Index In 'Fear' Zone

With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) to report quarterly earnings at $1.36 per share on revenue of $8.32 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Medtronic shares gained 0.7% to $93.44 in after-hours trading.</li>
<li>Analysts are expecting Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) to post quarterly earnings at $1.78 per share on revenue of $4.56 billion. The company will release earnings before the markets open. Baidu shares rose 0.3% to $97.72 in after-hours trading.</li>
<li>Sohu.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHU#NASDAQ">SOHU</a>) posted a non-GAAP net loss of $15 million for the fourth quarter, versus a year-ago loss of $11 million. Total revenues fell 5% year-over-year to $135 million. Sohu.com shares gained 1.6% to $14.90 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>After the markets close, Occidental Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) is projected to report quarterly earnings at 70 cents per share on revenue of $7.05 billion. Occidental Petroleum shares gained 0.6% to $48.33 in the after-hours trading session.</li>
<li>Analysts expect Fluor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) to post quarterly earnings at 77 cents per share on revenue of $4.42 billion before the opening bell. Fluor shares gained 0.9% to $43.80 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43730195/top-3-defensive-stocks-that-may-collapse-in-q1">Top 3 Defensive Stocks That May Collapse In Q1</a></li>
</ul>
Photo courtesy: Shutterstock

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

Financial giants have made a conspicuous bullish move on Medtronic. Our analysis of options history for Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) revealed 20 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $589,660, and 11 were calls, valued at $949,530.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $85.0 to $95.0 for Medtronic over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Medtronic options trades today is 942.55 with a total volume of 26,313.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Medtronic's big money trades within a strike price range of $85.0 to $95.0 over the last 30 days.
<h3>Medtronic Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739564131_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$5.7</td>
<td>$5.5</td>
<td>$5.6</td>
<td>$87.00</td>
<td>$280.0K</td>
<td>24</td>
<td>1.0K</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$0.9</td>
<td>$0.82</td>
<td>$0.83</td>
<td>$90.00</td>
<td>$207.5K</td>
<td>1.1K</td>
<td>2.5K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$4.85</td>
<td>$4.7</td>
<td>$4.75</td>
<td>$88.00</td>
<td>$118.7K</td>
<td>556</td>
<td>522</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.49</td>
<td>$1.43</td>
<td>$1.5</td>
<td>$95.00</td>
<td>$112.5K</td>
<td>2.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$2.33</td>
<td>$2.23</td>
<td>$2.23</td>
<td>$85.00</td>
<td>$111.5K</td>
<td>180</td>
<td>505</td>
</tr>
</tbody>
</table>

<h3>About Medtronic</h3>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
Following our analysis of the options activities associated with Medtronic, we pivot to a closer look at the company's own performance.
<h3>Current Position of Medtronic</h3>
<ul>
<li>With a trading volume of 4,822,351, the price of MDT is up by 0.56%, reaching $92.72.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 4 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Medtronic, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Medtronic Unusual Options Activity For February 14

On Thursday, Dexcom, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) fourth-quarter&nbsp;revenue rose 8% year-over-year to&nbsp;$1.114 billion,&nbsp;beating the analyst consensus <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimate of&nbsp;$1.104 billion</a>.
U.S. revenue rose by 4%, while international revenue rose by 17% on a reported basis and <a target="_blank" href="https://www.benzinga.com/25/02/43728537/dexcom-tops-sales-forecasts-as-international-growth-soars-19" rel="noreferrer noopener">19% on an organic basis</a>.
Outlook: Dexcom reaffirmed its FY25 guidance for revenue of $4.60 billion (vs. cons. of $4.61 billion), adjusted gross profit margin of around 64%–65%, and<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> adjusted operating margin of 21%</a>.
In December, Abbott Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reached an agreement with DexCom to settle all outstanding patent disputes related to continuous glucose monitoring products.
The agreement <a target="_blank" href="https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom" rel="noreferrer noopener">will</a> dismiss all pending cases in courts and patent offices worldwide. It also includes a provision that the parties will not litigate patent, trade dress, and design rights disputes with each other for the next 10 years. No financial payments are associated with the settlement from Abbott or Dexcom.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42274583/morgan-stanley-maintains-positive-medtech-outlook-despite-setbacks-in-2024-upgrades-intuitive-surgical-and-stryker-downgrades-nevro-and-glaukos" rel="noreferrer noopener">Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos</a>
Analyst Reactions: William Blair writes that DME's market share remained steady in Q4, and productivity has improved as planned, following a 40% commercial team expansion last year.
The analyst says the management expects further gains in productivity and another record year for new patient additions in 2025.&nbsp;&nbsp;
While the benefits of these improvements will take several quarters to materialize, especially as 2024 execution challenges fade in the second half, analyst Margaret Kaczor Andrew sees multiple growth drivers that could boost performance in 2025 and sustain revenue and earnings growth in the long term.
Andrew said that DexCom's challenges in 2024 may be temporary. She notes that DexCom is positioned for long-term growth, supported by its expanding product lineup, including G7, Dexcom One, and Stelo, and opportunities to reach new patient groups.
However, the analyst points out that DexCom's growth depends on adding new patients, particularly those with early-stage diabetes, with limited clinical data and reimbursement support.
Competition from major players like Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) and Abbott Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) could also impact DexCom's expansion by capturing a share of new or existing patients in the continuous glucose monitoring market.
Morgan Stanley analyst Patrick Wood maintains DexCom with an Equal-Weight rating and raises the price <a target="_blank" href="https://www.benzinga.com/quote/DXCM/analyst-ratings" rel="noreferrer noopener">target from $75 to $82</a>.
Canaccord Genuity analyst William Plovanic maintains DexCom with a Buy and raises the price target from $99 to $103.
Price Action: DXCM stock is up 6.22% at $89.32 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43737281/pfizers-talzennaxtandi-combo-improves-survival-outcomes-in-metastatic-castration-resistant-prostate-cancer" target="_blank" rel="noreferrer noopener">Pfizer's Talzenna/Xtandi Combo Improves Survival Outcomes In Metastatic Castration-Resistant Prostate Cancer</a></li>
</ul>

Analyst Color

DXCM

Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom

5 analysts have expressed a variety of opinions on Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $97.2, a high estimate of $109.00, and a low estimate of $89.00. This current average represents a 2.02% decrease from the previous average price target of $99.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1739383219_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Medtronic among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$89.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$109.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$97.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$98.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$93.00</td>
<td>$96.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Medtronic. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Medtronic compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Medtronic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Medtronic's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MDT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Medtronic analyst ratings.</a>
<h2>Delving into Medtronic's Background</h2>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
<h3>Financial Insights: Medtronic</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Medtronic's revenue growth over a period of 3 months has been noteworthy. As of 31 October, 2024, the company achieved a revenue growth rate of approximately 5.25%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Medtronic's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 15.11%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Medtronic's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.63%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Medtronic's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.41%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Medtronic's debt-to-equity ratio surpasses industry norms, standing at 0.58. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Medtronic In The Eyes Of 5 Experts

Nanovis, a leading developer and provider of nano surface technology that improves the biologic fixation of orthopedic, spine, and dental implants, announced today that certain of its nano surface technology assets and certain of its rights to intellectual property assets related to Sites Medical's OsteoSync&#x2122;&nbsp;titanium pads, have been acquired by Medtronic for use in the development of Medtronic's next generation PEEK interbody fusion devices.

Medtronic Acquires Nanovis Nano Surface Technology Assets And Rights Related To Sites Medical's OsteoSync For PEEK Interbody Fusion Devices; Terms Not Disclosed

Press Releases

Medtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference

Medtronic achieves CE Mark approval for BrainSense™ Adaptive deep brain stimulation and Electrode Identifier, a groundbreaking advance in personalized, sensing-enabled care for people with Parkinson's through innovative brain-computer interface technology

Medtronic announces CMS national coverage analysis for Symplicity™ Spyral Renal Denervation System

How HealthCare Industry is Leveraging Artificial Intelligence to Revolutionize Diagnostics and Early Disease Detection

Medtronic appoints Thierry Piéton as Chief Financial Officer

Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

Management

Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

Medtronic to announce financial results for its third quarter of fiscal year 2025

Medtronic reports third quarter fiscal 2025 financial results

Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's

Comments

Medtronic

뉴스

에 대한 최신 뉴스 Medtronic (NYSE:MDT) 주식

화요일, 2월 18, 2025

수요일, 11월 20, 2024

화요일, 11월 19, 2024

화요일, 8월 20, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌